title: [Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
abstract: Our study presents the results of ALL treatment from year 1995 to 2002 according to modified BFM protocol at the Department of Hematology of the University Children's Hospital, Belgrade. Modification was necessary due to inadequate drug and diagnostic reagent supply at that time and related mainly to reduced intensity of therapy and difference of definition of risk factors in relation to original BFM protocol. A total of 69 patients were treated, 36 girls (52.2%) and 33 boys (47.8%), mean age 4.5 years (range 0.4-16.8 yrs.). Thirteen children were classified as high risk, out of whom, one had Down syndrome, two had earlier corticosteroid treatment, nine were with T immunophenotype, out of whom three were poor prednisone responders and one was female infant. Clinical and laboratory parameters on diagnosis in our group were similar to the characteristics of patients in large published studies which exclude selection bias. There were four toxic deaths (5.8%) and ten relapses (14.5%). Five year event-free survival (EFS) with median follow-up of 5.2 years (range 2.2-9.2 years) was 70%.
authors.forename: Dragana
authors.initials: D
authors.lastname: Janić
authors.forename: Lidija
authors.initials: L
authors.lastname: Dokmanović
authors.forename: Nada
authors.initials: N
authors.lastname: Jovanović
authors.forename: Dejan
authors.initials: D
authors.lastname: Skorić
authors.forename: Jelena
authors.initials: J
authors.lastname: Lazić
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D015996:Survival Rate; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin